OPT News and Press, Opthea Limited From 07/08/21

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Opthea (OPT) announces that the FDA has granted Fast Track designation for its VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with neovascular (wet) age-related macular degeneration ((AMD)).Fast Track status provides fo...

MELBOURNE, Australia, July 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce that the U.S. Food and Drug Administration (...

Shares of Opthea (NASDAQ: OPT) were skyrocketing 18% as of 3:22 p.m. EDT on Wednesday after jumping as much as 88.7% earlier in the day. The huge gain didn't result from the company's own news. Instead, some investors appear to think that positive safety results from a clinical stud...

Shares of Opthea (OPT) are up 41% in afternoon trading, possibly due to a data release yesterday from Clearside Biomedical (CLSD) on its wet age-related macular degeneration ("AMD") candidate.Earlier in the day, Opthea reached a 52-week high of $16.23.In a phase 2b trial, Opthea's lead candid...

Gainers: Opthea (OPT) +47%, Kindred Biosciences (KIN) +45%, Aprea Therapeutics (APRE) +38%, Altimmune (ALT) +21%, BriaCell Therapeutics (BCTX) +15%.Losers: Inhibikase Therapeutics (IKT) -24%, Paratek Pharmaceuticals (PRTK) -14%,...

MELBOURNE, Australia, June 14, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mrs. Karen Adams as Vice ...

Board expands strengths in clinical and commercialization strategy OPT-302 pivotal Phase 3 trials for wet age-related macular degeneration (AMD) on track to reporting top-line data in 2023 MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- Opthea Limited...

Opthea Limited (OPT) announced that Mr. Michael Tonroe has resigned as company secretary and chief financial officer.The move is effective from June 24, 2021.The Company has begun a search for a permanent CFO.Mr. Tonroe will remain company secretary and CFO until the effective date of his res...

MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the Company, with effect 24 June 2021. Opthea has initiated a search for a permanent replacemen...